Hep b ig im
Products billed under this code include HyperHepB, Nabi-Hb.
Payment limit per 1 ML, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include HyperHepB, Nabi-Hb.
Payment limit per 1 ML, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| HyperHepB | Grifols USA, LLC | 13533-0636-01 | 1 | $138.229 |
| HyperHepB | Grifols USA, LLC | 13533-0636-03 | 1 | $138.229 |
| HyperHepB | Grifols USA, LLC | 13533-0636-05 | 5 | $691.145 |
| Nabi-Hb | ADMA Biologics, Inc | 69800-4202-01 | 1 | $138.229 |
| Nabi-Hb | ADMA Biologics, Inc | 69800-4203-01 | 5 | $691.145 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $138.229 | +$1.277 | 1 ML | Hep b ig im | v1, posted September 17, 2026 |
| 3Q26 | $136.952 | −$3.257 | 1 ML | Hep b ig im | v1, posted September 15, 2026 |
| 2Q26 | $140.209 | +$2.381 | 1 ML | Hep b ig im | v1, posted September 15, 2026 |
| 1Q26 | $137.828 | +$3.634 | 1 ML | Hep b ig im | v1, posted September 15, 2026 |
| 4Q25 | $134.194 | +$3.53 | 1 ML | Hep b ig im | v1, posted September 8, 2026 |
| 3Q25 | $130.664 | −$12.551 | 1 ML | Hep b ig im | v1, posted March 10, 2026 |
| 2Q25 | $143.215 | −$3.097 | 1 ML | Hep b ig im | v1, posted March 10, 2026 |
| 1Q25 | $146.312 | +$6.381 | 1 ML | Hep b ig im | v1, posted December 19, 2025 |
| 4Q24 | $139.931 | −$3.84 | 1 ML | Hep b ig im | v1, posted June 11, 2025 |
| 3Q24 | $143.771 | +$2.656 | 1 ML | Hep b ig im | v1, posted June 11, 2025 |
| 2Q24 | $141.115 | +$3.223 | 1 ML | Hep b ig im | v1, posted March 11, 2025 |
| 1Q24 | $137.892 | +$0.311 | 1 ML | Hep b ig im | v1, posted December 19, 2024 |
| 4Q23 | $137.581 | +$0.837 | 1 ML | Hep b ig im | v1, posted October 10, 2024 |
| 3Q23 | $136.744 | +$4.986 | 1 ML | Hep b ig im | v1, posted June 5, 2024 |
| 2Q23 | $131.758 | +$3.707 | 1 ML | Hep b ig im | v1, posted February 23, 2024 |
| 1Q23 | $128.051 | −$7.828 | 1 ML | Hep b ig im | v1, posted December 6, 2023 |
| 4Q22 | $135.879 | −$2.994 | 1 ML | Hep b ig im | v1, posted June 22, 2023 |
| 3Q22 | $138.873 | −$0.044 | 1 ML | Hep b ig im | v1, posted June 9, 2023 |
| 2Q22 | $138.917 | +$3.324 | 1 ML | Hep b ig im | v1, posted December 14, 2022 |
| 1Q22 | $135.593 | +$5.285 | 1 ML | Hep b ig im | v1, posted June 8, 2022 |
| 4Q21 | $130.308 | −$1.549 | 1 ML | Hep b ig im | v1, posted June 2, 2022 |
| 3Q21 | $131.857 | +$5.582 | 1 ML | Hep b ig im | v1, posted June 2, 2022 |
| 2Q21 | $126.275 | −$0.583 | 1 ML | Hep b ig im | v1, posted March 1, 2022 |
| 1Q21 | $126.858 | – | 1 ML | Hep b ig im | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.